Spyre Therapeutics (SYRE) EBITDA (2015 - 2026)

Spyre Therapeutics has reported EBITDA for 12 years, with the latest figure at -$45.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 14.8% year-over-year to -$45.6 million; the trailing twelve-month figure through Mar 2026 stood at -$201.6 million (up 5.94% YoY), and the FY2025 full-year result was -$209.6 million, changed 0.48% from the prior year.
• EBITDA for Q1 2026 stood at -$45.6 million, up from -$57.2 million in the prior quarter.
• The five-year high for EBITDA was -$18.3 million in Q3 2023, with the low at -$159.2 million in Q2 2023.
• Historically, EBITDA has averaged -$46.5 million across 5 years, with a median of -$45.6 million in 2026.
• Annual changes were most pronounced in 2023 — EBITDA plunged 610.19% — and 2024, when it surged 72.28%.
• Spyre Therapeutics' EBITDA stood at -$19.2 million in 2022, then plunged by 139.61% to -$45.9 million in 2023, then slumped by 33.41% to -$61.3 million in 2024, then rose by 6.66% to -$57.2 million in 2025, then gained by 20.17% to -$45.6 million in 2026.
• The last three EBITDA figures came in at -$45.6 million (Q1 2026), -$57.2 million (Q4 2025), and -$56.9 million (Q3 2025), per Business Quant data.